Average payments for the NSAID meloxicam are up sharply since 2020 and the drug consumed more than 30% of the anti-inflammatory drug spend in 2025.
Average payments for the NSAID meloxicam are up sharply since 2020 and the drug consumed more than 30% of the anti-inflammatory drug spend in 2025.